<DOC>
	<DOCNO>NCT02625857</DOCNO>
	<brief_summary>The purpose study find evaluate recommend Phase 2 dose ( RP2D ) JNJ-64041809 , live attenuate double delete ( LADD ) Listeria monocytogenes ( bacteria two virulence gene , encode molecule help cause disease , remove ) administer intravenously participant metastatic castration-resistant prostate cancer ( mCRPC ) .</brief_summary>
	<brief_title>Safety &amp; Immunogenicity JNJ-64041809 , Live Attenuated Double-deleted Listeria Immunotherapy , Participants With Metastatic Castration-resistant Prostate Cancer</brief_title>
	<detailed_description>This first-in-human ( FIH ) , Phase 1 , open-label , multicenter 2-part study . The Part 1 study Dose Escalation phase determine recommend Phase 2 dose ( RP2D ) base safety pharmacodynamic assessment Part 2 Dose Expansion Phase evaluate 2 expansion cohort ( Cohort 2A 2B ) RP2D JNJ-64041809 determine Part 1 . The study consist Screening Period ( sign inform consent immediately first dose ) , open-label Treatment Period ( first dose study drug End-of-Treatment Visit ) ; Post treatment Follow-up Period ( End-of Treatment Visit study discontinuation ) . Participants primarily evaluate RP2D . Participants safety evaluate throughout study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms , Castration-Resistant</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate progressive metastatic disease , opinion investigator , require initiation new treatment . The assessment disease progression base either PSA rise , new progressive soft tissue disease ( base compute tomography [ CT ] magnetic resonance image [ MRI ] scan ) , new progressive bony disease base radionuclide bone scan 18Fsodium fluoride positron emission tomography/computed tomography [ NaF PET/CT ] scan ) . Participants consider Cohort 2B must , addition , primary metastatic lesion amenable tumor biopsy Must receive least 2 prior approve therapy Ongoing androgen depletion therapy Gonadotropin Releasing Hormone analog inhibitor , orchiectomy ( surgical medical castration ) Serum testosterone level less ( &lt; ) 50 nanogram per deciliter ( ng/dL ) determine within 4 week prior start study drug For participant previously treat first generation antiandrogens ( ie , flutamide , nilutamide , bicalutamide ) , discontinuation flutamide nilutamide therapy must occur great ( &gt; ) 4 week ( &gt; 6 week bicalutamide ) prior start study drug evidence antiandrogen withdrawal response ( decline serum PSA ) Untreated brain metastasis . Participants must complete treatment brain metastasis , neurologically stable steroid , least 28 day prior first dose study drug Untreated spinal cord compression History listeriosis vaccination listeriabased vaccine prophylactic vaccine ( example influenza , pneumococcal , diphtheria , tetanus , pertussis [ dTP/dTAP ] ) within 28 day study treatment Known allergy penicillin trimethoprim/sulfamethoxazole . Participants allergic one antibiotic allow enroll Concurrent treatment anti Tumor necrosis factor ( TNF ) alpha therapy , systemic corticosteroid ( prednisone dose &gt; 10 mg per day equivalent ) immune suppressive drug within 2 week prior Screening . Steroids topical , inhaled , nasal ( spray ) , ophthalmic solution permit</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Prostatic Neoplasms , Castration-Resistant</keyword>
	<keyword>JNJ-64041809</keyword>
	<keyword>Listeria monocytogenes</keyword>
</DOC>